Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.41 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.41 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.41 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305361 | 1.00 | LMNA (0.42) | LMNAPOLBHDAC1HDAC3HDAC2 | |
| SCHEMBL29488477 | 1.00 | LMNA (0.42) | LMNAPOLBHDAC1HDAC3HDAC2 | |
| SCHEMBL1306924 | 0.93 | HDAC6 (0.42) | LMNAHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL29488475 | 0.93 | HDAC6 (0.42) | LMNAHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL1306921 | 0.93 | HDAC6 (0.42) | LMNAHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL1307956 | 0.91 | KDM4E (0.46) | LMNAPOLBPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL1307959 | 0.91 | KDM4E (0.46) | LMNAPOLBPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL1306689 | 0.91 | PTPN1 (0.48) | LMNAPOLBHDAC1HDAC3HDAC2 | |
| SCHEMBL29488458 | 0.91 | PTPN1 (0.48) | LMNAPOLBHDAC1HDAC3HDAC2 | |
| SCHEMBL1306686 | 0.91 | PTPN1 (0.48) | LMNAPOLBHDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | CRYSTALGENOMICS, INC. (KR) | 2022-09-15 | — | — | US | claimed |
| WO-2022177054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | 크리스탈지노믹스(주) | 2022-08-25 | — | — | WO | claimed |
| EP-4026544-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | Crystalgenomics, Inc. (KR) | 2022-07-13 | — | — | EP | claimed |
| US-20210346321-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | CRYSTALGENOMICS, INC. (KR) | 2021-11-11 | — | — | US | claimed |
| WO-2021045392-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | 크리스탈지노믹스(주) | 2021-03-11 | — | — | WO | claimed |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2020-09-10 | — | — | US | claimed |
| EP-3640239-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2020-04-22 | — | — | EP | claimed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | claimed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | claimed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | claimed |
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | CRYSTALGENOMICS, INC. (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4155292-A1 | METHOD FOR PRODUCING PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE | Crystalgenomics, Inc. (KR) | 2023-03-29 | — | — | EP | disclosed |
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | CRYSTALGENOMICS, INC. (KR) | 2022-09-15 | — | — | US | disclosed |
| WO-2022177054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | 크리스탈지노믹스(주) | 2022-08-25 | — | — | WO | disclosed |
| EP-4026544-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | Crystalgenomics, Inc. (KR) | 2022-07-13 | — | — | EP | disclosed |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2020-09-10 | — | — | US | disclosed |
| EP-3640239-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2020-04-22 | — | — | EP | disclosed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | PDCD1, HDAC1, HDAC5 | LMNA 1269/4885POLB 358/4885HDAC1 2/4885 |
| US-20210346321-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | AGPAT5, NOTUM, HADH | LMNA 4213/4885POLB 3794/4885HDAC1 2152/4885 |
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | DOHH, CYP51A1, ASAH2 | LMNA 2776/4885POLB 4347/4885HDAC1 2369/4885 |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | LMNA 1637/4885POLB 626/4885HDAC1 1/4885 |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | DOHH, CYP51A1, CYP46A1 | LMNA 2745/4885POLB 4228/4885HDAC1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.